Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Return on Invested Capital (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Return on Invested Capital for 8 consecutive years, with 0.2% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Invested Capital rose 43.0% year-over-year to 0.2%, compared with a TTM value of 0.2% through Sep 2025, up 43.0%, and an annual FY2024 reading of 1.04%, down 102.0% over the prior year.
  • Return on Invested Capital was 0.2% for Q3 2025 at CytomX Therapeutics, down from 0.59% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 2.91% in Q1 2025 and bottomed at 2.08% in Q4 2024.
  • Average Return on Invested Capital over 3 years is 0.15%, with a median of 0.02% recorded in 2023.
  • The sharpest move saw Return on Invested Capital plummeted -205bps in 2024, then surged 313bps in 2025.
  • Year by year, Return on Invested Capital stood at 0.02% in 2023, then crashed by -9128bps to 2.08% in 2024, then soared by 110bps to 0.2% in 2025.
  • Business Quant data shows Return on Invested Capital for CTMX at 0.2% in Q3 2025, 0.59% in Q2 2025, and 2.91% in Q1 2025.